News
Videos
Conferences
Events
Resources
Subscribe

|Videos|January 14, 2016

Managing Side Effects

Episodes in this series

EP. 1 Multiple Myeloma Defined

EP. 1 Multiple Myeloma Defined

EP. 2 The Detection of Multiple Myeloma

EP. 2 The Detection of Multiple Myeloma

EP. 3 Understanding Your Bone Marrow Biopsy

EP. 3 Understanding Your Bone Marrow Biopsy

EP. 4 Initial Reactions Upon a Diagnosis

EP. 4 Initial Reactions Upon a Diagnosis

EP. 5 Managing Multiple Myeloma

EP. 5 Managing Multiple Myeloma

EP. 6 Managing Side Effects

EP. 6 Managing Side Effects

EP. 7 Education Is Power

EP. 7 Education Is Power

EP. 8 Preventive Measures of Stem Cell Transplants

EP. 8 Preventive Measures of Stem Cell Transplants

EP. 9 Stem Cell Transplantation: What to Expect After

EP. 9 Stem Cell Transplantation: What to Expect After

EP. 10 Stem Cell Transplantation: Preventive Measures

EP. 10 Stem Cell Transplantation: Preventive Measures

EP. 11 Understanding and Managing Relapse

EP. 11 Understanding and Managing Relapse

EP. 12 Setting Realistic Expectations After Diagnosis

EP. 12 Setting Realistic Expectations After Diagnosis

EP. 13 Considerations to Optimize Your Health

EP. 13 Considerations to Optimize Your Health

null

Newsletter

Stay up to date on cancer updates, research and education

Related Content

FDA

FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma

January 29th 2026

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

January 27th 2026

As patients with advanced cancer near the end of life, reducing unnecessary medications may help prioritize comfort, quality of life, and symptom relief: © stock.adobe.com

Rethinking Medications at the End of Life for Patients With Advanced Cancer

January 27th 2026

FDA

FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma

January 27th 2026

Dr. Surbhi Sidana

How Tecvayli With Darzalex Works to Treat Multiple Myeloma

ByDr. Surbhi Sidana

January 19th 2026

Trending on CURE

Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows

FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma

Expert insights into Biomarker-Driven Care and Emerging Targets in GI Cancer

Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC

FDA Approves Larger Nelarabine Vial for Some Leukemias and Lymphomas